This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

This study has been completed.
Information provided by:
Weill Medical College of Cornell University Identifier:
First received: November 1, 1999
Last updated: October 9, 2009
Last verified: October 2009

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of muJ591 monoclonal antibody in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Condition Intervention Phase
Prostate Cancer Biological: monoclonal antibody muJ591 Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase I Trial of Monoclonal Antibody muJ591 in Patients With Hormone-Independent Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Weill Medical College of Cornell University:

Estimated Enrollment: 30
Study Start Date: June 1998
Detailed Description:

OBJECTIVES: I. Define the toxicity and maximum tolerated dose of monoclonal antibody muJ591 in patients with hormone independent prostate cancer. II. Define the pharmacokinetics and biodistribution of monoclonal antibody muJ591 in these patients. III. Define the human antimouse antibody response to this therapy. IV. Define the preliminary efficacy of this therapy in these patients.

OUTLINE: This is a dose escalation study. Patients receive a single dose of intravenous iodine I 131-labeled monoclonal antibody muJ591 on day 0, combined with an unlabeled (cold) dose of monoclonal antibody muJ591. Anterior and posterior imaging is obtained 1 hour after labeled muJ591 administration and on days 0, 2, 4, and 6. Subsequent cohorts of 3-6 patients receive fixed iodine-labeled doses with escalating cold doses of monoclonal antibody muJ591 until the maximum tolerated dose is reached. Patients are followed for a minimum of 8 weeks after muJ591 therapy or until disease progression. Patients with stable or responding disease who are human anti-mouse antibody negative may receive subsequent treatments at the discretion of the principal investigator.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

DISEASE CHARACTERISTICS: Histologically proven metastatic adenocarcinoma of the prostate, defined by: Abnormal CT, MRI, or bone scan and/or Rising prostate specific antigen (PSA) levels (on 3 consecutive occasions over at least 6 weeks) despite hormonal therapy PSA at least 2.0 at study entry No active CNS metastases

PATIENT CHARACTERISTICS: Age: 21 and over Performance status: Karnofsky 60-100% Life expectancy: At least 6 months Hematopoietic: WBC greater than 3,500/mm3 Platelet count greater than 100,000/mm3 No serious hematologic disease Hepatic: SGOT less than 2.0 times upper limit of normal Bilirubin less than 1.5 mg/dL No serious hepatic disease Renal: Creatinine less than 2.0 mg/dL Calcium less than 13.5 mg/dL No serious renal disease Cardiovascular: No active angina No New York Heart Association class III-IV No other serious cardiac disease Pulmonary: No serious respiratory disease Other: No active uncontrolled infection Evidence of pre-existing antimouse antibody at the time of screening

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks since prior cytotoxic chemotherapy Endocrine therapy: At least 6 weeks since prior adrenal hormone inhibitors or corticosteroid therapy Antiandrogen therapy must be discontinued prior to measuring PSA values Luteinizing hormone-releasing hormone analog must be maintained during study OR must be discontinued at least 10 weeks prior to study entry (for 28 day depot preparation) or 24 weeks prior to study entry (for 3 month depot preparation) Radiotherapy: At least 6 weeks since prior radiotherapy Surgery: Not specified

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003391

United States, New York
New York Presbyterian Hospital - Cornell Campus
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
Study Chair: Neil H. Bander, MD Weill Medical College of Cornell University
  More Information Identifier: NCT00003391     History of Changes
Other Study ID Numbers: CDR0000066389
Study First Received: November 1, 1999
Last Updated: October 9, 2009

Keywords provided by Weill Medical College of Cornell University:
adenocarcinoma of the prostate
stage IV prostate cancer
recurrent prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on August 22, 2017